Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Roswell Park Cancer Institute Stories

2010-04-14 08:46:00

BUFFALO, N.Y., April 14 /PRNewswire/ -- Kinex Pharmaceuticals (Buffalo, NY) is scheduled to make four presentations at the 101st Annual Meeting of the American Association for Cancer Research (AACR) that will take place at the Walter E. Washington Convention Center in Washington, DC on April 17-21, 2010. The theme of the meeting, "Conquering Cancer through Discovery Research" is expected to recruit more than 20,000 cancer researchers, health professionals, cancer survivors and advocates and...

2010-04-12 05:15:00

Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads consortium of investigators across U.S. LOS ANGELES, April 12 /PRNewswire-USNewswire/ -- Aptium Oncology, Inc. today announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers. Brian G.M. Durie, M.D.,...

2010-03-15 15:29:08

BUFFALO, N.Y. -- Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly. However, a new study by University at Buffalo researchers shows that persons of different ethnic groups have different ideas and opinions about whether they are at risk for developing cancer -- perceptions that can influence whether they undergo screening. The study results reveal that blacks feel less at...

2010-01-29 07:30:00

DETROIT, Jan. 29 /PRNewswire-USNewswire/ -- After a 10-month nationwide search, Gerold Bepler, M.D., Ph.D., has been named the new president and chief executive officer of the Barbara Ann Karmanos Cancer Institute. A thoracic oncologist, Dr. Bepler will begin his new position Feb. 1, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO) In addition to his chief administrative duties, Dr. Bepler will also serve as principal investigator of Karmanos' National Cancer...

2009-12-09 10:30:00

NCCN updates the NCCN Guidelines for Non-Small Cell Lung Cancer to include guidance on maintenance therapy, several new therapeutic recommendations for specific patients with Non-Small Cell Lung Cancer, and a revised staging system. FORT WASHINGTON, Pa., Dec. 9 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) to incorporate a new section about maintenance therapy, a number of new...

2009-12-03 15:50:00

SOUTHBRIDGE, Mass., Dec. 3 /PRNewswire/ -- The Cancer Center at Harrington has received approval to treat its first patients, Harrington Hospital announced today. "We expect to start seeing patients immediately," said Diane Becquart, Director of The Cancer Center at Harrington. The approval was granted today by the Massachusetts Department of Public Health following a safety and quality review of the facility. The opening of The Cancer Center at Harrington means that patients in the...

2009-11-23 13:03:00

Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). FORT WASHINGTON, Pa., Nov. 23 /PRNewswire-USNewswire/ -- Two recent FDA approvals have prompted the...

2009-11-20 10:39:00

NCCN program on Discovery Health Channel profiles patients undergoing treatment for metastatic breast cancer and their physicians' use of the NCCN Clinical Practice Guidelines in Oncology(TM) for Breast Cancer to determine an individualized treatment regimen. The program, which provides free CME credits, premieres on Sunday, November 22 at 7:00 am EST. FORT WASHINGTON, Pa., Nov. 20 /PRNewswire-USNewswire/ -- Although October (National Breast Cancer Awareness Month) is behind us, it...

2009-11-10 08:12:00

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, Pa., Nov. 10 /PRNewswire-USNewswire/ -- The National Comprehensive...

2009-11-03 09:44:00

The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, Pa., Nov. 3 /PRNewswire-USNewswire/ -- Following the...